Skip to main content
← All trials
Transthyretin Amyloidosis (ATTR) With CardiomyopathyDrugPhase 3

What this study is

The purpose of this study is to obtain safety, efficacy, and pharmacodynamic data on the use of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy who continued on extended use of vutrisiran, or switched from patisiran.

What's being tested

  • Vutrisiran

    Intervention · DRUG

    Vutrisiran administered SC q3M

Study details

Official title
An Open-Label Extension Study to Assess the Safety and Efficacy of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
Sponsor
Alnylam Pharmaceuticals
Conditions
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Enrolling
700 people
Starts
2024-12-03
Est. completion
2028-03-31
Design
Open-label, single group, Phase 3
Record
View on ClinicalTrials.gov ↗